8-K: Pasithea Therapeutics Prices \$5 Million Public Offering, Closes Offering and Receives Additional \$1.3 Million from Warrant Exercises

Pasithea Therapeutics announces a \$5 million public offering and subsequent closing, with an additional \$1.3 million received from warrant exercises.

Summary

• Pasithea Therapeutics Corp. has announced the pricing and closing of a public offering.
• The offering consisted of 3,571,428 shares of common stock (or pre-funded warrants) and accompanying Series C and Series D warrants.
• The combined offering price was \$1.40 per share (or pre-funded warrant) and accompanying warrants.
• The Series C warrants have an exercise price of \$1.40 per share and expire five years after issuance.
• The Series D warrants have an exercise price of \$1.40 per share and expire 18 months after issuance.
• The offering closed on May 7, 2025, with H.C. Wainwright & Co. acting as the exclusive placement agent.
• Gross proceeds from the offering are expected to be approximately \$5.0 million before deducting fees and expenses.
• Simultaneously with the closing, certain investors exercised Series D warrants to purchase 914,286 shares, resulting in additional gross proceeds of approximately \$1.3 million.
• The aggregate gross proceeds from the offering and warrant exercises were approximately \$6.3 million.
• The company intends to use the net proceeds for general corporate purposes, including research, clinical trials, and potential acquisitions.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The company successfully completed a public offering and received additional funds from warrant exercises. However, the offering also involves dilution, and the company's future success depends on the progress of its clinical trials and research.

Positives

• The company successfully raised \$5 million through a public offering.
• The company secured an additional \$1.3 million through the exercise of warrants.
• The company has access to \$6.3 million in gross proceeds for general corporate purposes.
• The company has flexibility in using the proceeds for research, clinical trials, and potential acquisitions.

Negatives

• The offering involves dilution of existing shareholders' equity.
• The company is reliant on future warrant exercises for additional capital.

Risks

• Future clinical trial results may not match results observed to date, may be negative or ambiguous, or may not reach the level of statistical significance required for regulatory approval.
• The company's actual results could be materially different from forward-looking statements due to various risks and uncertainties.

Future Outlook

The company intends to use the net proceeds from the offering for general corporate purposes, including research, clinical trials, the development of new biological and pharmaceutical technologies, investing in or acquiring companies that are synergistic with or complementary to the Company's technologies, licensing activities related to its current and future product candidates, and to the development of emerging technologies, investing in or acquiring companies that are developing emerging technologies, licensing activities, or the acquisition of other businesses and working capital.

Industry Context

The announcement reflects a common financing strategy for clinical-stage biotechnology companies, which often require significant capital to fund research and development activities. The funds raised will enable Pasithea Therapeutics to advance its pipeline and explore strategic opportunities.

Comparison to Industry Standards

• Comparable companies in the biotechnology sector, such as Amylyx Pharmaceuticals and Biohaven Pharmaceuticals, have also utilized public offerings and warrant exercises to raise capital for drug development.
• The size of the offering (\$5 million) is relatively small compared to some larger biotech financings, but is appropriate for a company at Pasithea's stage of development.
• The terms of the warrants (exercise price and expiration dates) are within the typical range for biotech financings.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• Employees may benefit from increased funding for research and development.
• Customers may benefit from the development of new treatments.
• The company's financial stability is improved, benefiting suppliers and creditors.

Next Steps

• The company will use the net proceeds from the offering for general corporate purposes.
• The company will continue ongoing research and pre-clinical studies.
• The company will conduct clinical trials.
• The company will develop new biological and pharmaceutical technologies.
• The company may invest in or acquire synergistic companies.
• The company will pursue licensing activities related to its product candidates.

Key Dates

Keywords

public offering, warrants, capital raise, biotechnology, Pasithea Therapeutics, KTTA, clinical trials, research, financing